The PERT Consortium CEO Michelle Lanno to Step Down at Year’s End

July 20, 2026—Michelle Lanno, Chief Executive Officer of The PERT Consortium, announced she will be stepping down from her role effective December 31, concluding more than a decade of leadership that began with the organization’s founding in 2015.

Imperative Care Launches Ikon 24 Pro Guidewire for Stroke Procedures

July 20, 2026—Imperative Care announced the launch of the Ikon 24 Pro guidewire.

Abbott’s 76-mm Esprit-BTK System Receives FDA Approval

July 16, 2026—The FDA has approved Abbott’s longer length (76-mm) Esprit below-the-knee (BTK) system, a dissolving resorbable scaffold for the treatment of chronic limb-threatening ischemia (CLTI).

Xeltis aXess Vascular Access Device for Hemodialysis Launched in Europe

July 15, 2026—Xeltis announced the official start of the European commercialization of aXess vascular access device for patients requiring hemodialysis.

Delcath Commences DELUMA Trial of Hepzato in Liver-Dominant Metastatic Breast Cancer

July 14, 2026—Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the first patient has been dosed at the European Institute of Oncology in Milan, Italy, in a global phase 2 clinical trial evaluating the company’s Hepzato in combination with standard of care (SOC) treatment for liver-dominant metastatic breast cancer (mBC).

Vesalio Appoints Greg Cook as Chief Commercial Officer

July 14, 2026—Vesalio announced the appointment of Greg Cook as Chief Commercial Officer, responsible for leading the company’s commercial strategy, market development, sales, marketing, and commercial operations.

Immediate Adoption of Enhanced Radiation Protection in Catheterization Labs Recommended in Multisociety Statement

July 14, 2026—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that a multisociety expert consensus statement on radiation protection in catheterization labs was published by David G. Rizik, MD, et al in JSCAI.

Fluidx’s GPX Embolic Device Meets Primary Endpoints in Pivotal Trial

July 14, 2026—Fluidx Medical Technology, Inc. announced results from a pivotal clinical trial evaluating the company’s GPX embolic device.